OTHAIR Trademark

Trademark Overview


On Wednesday, September 22, 2021, a trademark application was filed for OTHAIR with the United States Patent and Trademark Office. The USPTO has given the OTHAIR trademark a serial number of 97039352. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Sunday, June 9, 2024. This trademark is owned by PROTHENA BIOSCIENCES LIMITED. The OTHAIR trademark is filed in the Pharmaceutical Products category with the following description:

Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetes
othair

General Information


Serial Number97039352
Word MarkOTHAIR
Filing DateWednesday, September 22, 2021
Status731 - SECOND EXTENSION - GRANTED
Status DateSunday, June 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 25, 2023

Trademark Statements


Goods and ServicesBiopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system; Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetes
Translation of Words in MarkThe English translation of "OTHAIR" in the mark is "patients".

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 25, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePROTHENA BIOSCIENCES LIMITED
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDublin 2 D02VK60
IE

Party NamePROTHENA BIOSCIENCES LIMITED
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDublin 2 D02T804
IE

Trademark Events


Event DateEvent Description
Saturday, September 25, 2021NEW APPLICATION ENTERED
Monday, October 25, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 24, 2022ASSIGNED TO EXAMINER
Friday, July 1, 2022NON-FINAL ACTION WRITTEN
Friday, July 1, 2022NON-FINAL ACTION E-MAILED
Friday, July 1, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, December 20, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 3, 2023ASSIGNED TO LIE
Friday, March 3, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 20, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 5, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 25, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 25, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 20, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 19, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, December 19, 2023SOU EXTENSION 1 FILED
Tuesday, December 19, 2023SOU EXTENSION 1 GRANTED
Thursday, December 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sunday, June 9, 2024SOU TEAS EXTENSION RECEIVED
Monday, June 10, 2024SOU EXTENSION 2 FILED
Monday, June 10, 2024SOU EXTENSION 2 GRANTED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED